ACIU

AC Immune SA ACIU

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,822 of 2,925

Why it scores 15Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$3.57M

Quarter to Dec 31

Net income

$-70.45M

Quarter to Dec 31

Free cash flow

$-70.16M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$58.24M total
BVF INC/IL
$47.18M0.0%
WELLS FARGO & COMPANY/MN
$2.39M0.0%
RENAISSANCE TECHNOLOGIES LLC
$2.00M+34.6%
MILLENNIUM MANAGEMENT LLC
$1.84M-2.4%
BlackRock, Inc.
$1.24M-1.0%
DIMENSIONAL FUND ADVISORS LP
$812.1K-12.8%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$554.4K-42.6%
CITADEL ADVISORS LLC
$494.1K-22.3%
MORGAN STANLEY
$313.7K+47.7%
TWO SIGMA INVESTMENTS, LP
$244.7K+163.0%
Qube Research & Technologies Ltd
$219.8KNew
UBS Group AG
$203.8K-15.8%
GEODE CAPITAL MANAGEMENT, LLC
$147.2K-2.7%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$127.0K-40.2%
Jump Financial, LLC
$57.3K+116.3%
JANE STREET GROUP, LLC
$46.4K-66.2%
Verdad Advisers, LP
$38.8KNew
China Universal Asset Management Co., Ltd.
$38.5K-9.3%
GOLDMAN SACHS GROUP INC
$34.5K-33.0%
Quadrature Capital Ltd
$30.9KNew
SG Americas Securities, LLC
$25.0KNew
AXQ CAPITAL, LP
$24.7KNew
Quinn Opportunity Partners LLC
$24.0K0.0%
Silverberg Bernstein Capital Management LLC
$23.8K0.0%
EFG International AG
$23.6K0.0%
See all 43 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ACIU

Earnings Per Share

13fpro.ai/company/ACIU

Loading ratio trend…

ACIU key financials by period

Reported revenue, net income and operating margin by fiscal year, from AC Immune SA's annual filings on SEC EDGAR.

AC Immune SA reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$3.6M$-70.4M—
FY 2024$27.3M$-50.9M-191.8%
FY 2023$14.8M$-54.2M—
FY 2022$3.9M$-70.8M—
FY 2020$15.4M$-61.9M—
FY 2019$110.5M$45.4M40.3%
Source: ACIU filings on SEC EDGAR →

ACIU insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About AC Immune SA (ACIU): stock profile, AI score and financials

AC Immune SA (ACIU) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACIU at 14.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,822 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (1.7) and profitability (2.2), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2025), AC Immune SA reports quarterly revenue of $3.6M, net income of $-70.4M, free cash flow of $-70.2M. Top institutional holders of ACIU by reported 13-F value include BVF, WELLS FARGO & COMPANY, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ACIU trades on the Nasdaq exchange and files with the SEC under CIK 1651625. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACIU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AC Immune SA directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1651625 →